Seeking Alpha

Andrew Nava's  Instablog

Andrew Nava
Send Message
Andrew Nava LLC is a healthcare focused consulting and investment firm. Prior to launching Andrew Nava LLC, I was a venture analyst, buy-side analyst, and most recently, the Director of Research at Actin Biomed, a New York-based healthcare investment firm where I was responsible for the medical,... More
My company:
Andrew Nava, LLC
  • What's Inside Our Daily Updates - Daily Biotech Milestones and Clinical Trial Data 0 comments
    Jun 16, 2010 7:18 PM | about stocks: ACUR, ANIP, CORT, CRIS, EPRS, ITMN, KERX, SLXP, VNDA

    Our database of clinical trial results, stock catalysts, and product sales is updated on a daily basis.  If you're too busy to check what's new on our site we also offer daily updates on new milestones, updates to our database and stocks to watch for the day.

    Here's an example email sent to clients on May 4, 2010 (chosen at random):

    NEW MILESTONES

    ACUR: KG and ACUR said they would file an NDA for Acurox in early 2011 (Note: FDA Anesthetic and Life Support Drugs and Drug Safety AdComm voted 19-1 against approval)
    BPAX: Expect GVAX clinical hold to be lifted (to partial hold) soon w/ new prostate CA trial at Hopkins anticipated to begin in 4Q10.
    CORT: Pivotal Cushings data for Corlux on track for 4Q10.
    CRIS: CUDC-101 enrollment is now complete, final trial data is expected at EORTC-NCI-AACR November 2010 (company has seen responses in gastric CA after 4 cycles).
    STEM: HuCNS-SC data presented at AANS

    DATABASE UPDATES

    CLDA (Santen deal), OMER (OMS103HP data), ANX (financing), BSDM (financing), AUXL (Xiaflex, Testim sales), TRGT (expanded AZN deal), CORT (warrant exercise), POZN (Q1 Treximet sales), ISPH (all sales for Q1), VRX, RPTP (Cysteamine NASH data), PPHM

    STOCK WATCH

    ITMN: PDUFA today
    CRXX: Up pre-market
    KERX: Continues upward trend w/ heavy volume pre-market
    SLXP: Up pre-market
    VNDA: Up pre-market on higher than expected Fanapt revenue

    RESEARCH - Not disclosed, coming soon

    Andrew Nava, LLC provides institutional and retail healthcare investors with buy-side equity research tools which focus on value-driven investing, profitable trading ideas and clinical, commercial, and regulatory catalysts. Our research is supported by consulting with KOL's, industry professionals, company management, and our database of clinical trial data and upcoming company milestones.

    As of June 2010, AndrewNava.com covers over 290 publicly-traded biotechnology and pharmaceutical companies, 100's of clinical trials from more than 1000 approved and development-stage drugs, devices and diagnostics, and over 800 company milestones across 17 different catalyst types.



    Disclosure: No positions
    Stocks: ACUR, ANIP, CORT, CRIS, EPRS, ITMN, KERX, SLXP, VNDA
Back To Andrew Nava's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.